Is there really a clinical benefit to using the new drugs for HFrEF in real life?

9 May 2026 (08:00 - 12:45)

Organised by:

Sign in to view the resources

About the speaker

Mr Virgilio Martinez Mateo

General Hospital La Mancha Centro, Alcazar de San Juan (Spain)

6 More presentations in this session

Presentation thumbnail

Association between low-dose aspirin use and serum uric acid levels in older adults: a cross-sectional analysis from the baseline survey of the LAPIS study

Doctor X. Wang (Beijing, CN)

Presentation thumbnail

Impact of cardiac myosin inhibitor therapy on treatment of hypertension in hypertrophic obstructive cardiomyopathy

Doctor K. Paik (Winston Salem, US)

Presentation thumbnail

Head-to-head randomized trials of atorvastatin and rosuvastatin: a systematic review and meta-analysis of changes in inflammatory biomarkers

Doctor A. Omayer (Dubai, AE)

Presentation thumbnail

Wild-type transthyretin amyloid cardiomyopathy: spironolactone as a therapeutic option?

Doctor A. Martins (Leiria, PT)

Presentation thumbnail

Let's talk about heart failure with preserved ejection fraction and mineralocorticosteroid receptor antagonists: real-world registry data

Doctor D. Besic (Zagreb, HR)

Access the full session

Session thumbnail

ePosters in pharmacology and pharmacotherapy (2)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

You may be interested in

Congress Presentation

State-of-the-art lecture on pharmacotherapy for acute coronary syndromes

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

Congress Presentation

Medical treatment works! Contemporary implementation into clinical practice

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources